LL-37 (5mg)

LL-37 is the only known human cathelicidin-derived peptide and is generated by proteolytic processing of the CAP18 precursor protein. It is expressed in various epithelial surfaces and immune cells, especially at barrier sites such as skin, airways, and the gastrointestinal tract.

Key characteristics of LL-37 in research contexts include:

• Innate immune effector: Interacts with microbial membranes and host pattern-recognition systems.
• Immunomodulator: Can either enhance or restrain inflammatory responses depending on cell type, activation state, and local cytokine milieu.
• Tissue homeostasis mediator: Has been studied in relation to epithelial repair, angiogenesis, and extracellular matrix remodeling.

Because LL-37 shows context-dependent behavior, it serves as a versatile probe for exploring how a single peptide can coordinate antimicrobial defense with controlled inflammation and tissue repair.

LL-37 and Inflammatory Diseases
LL-37 is frequently detected in inflamed tissues and has been evaluated in models of psoriasis, lupus, rheumatoid arthritis, atherosclerosis, and other immune-mediated conditions. Depending on the local environment, LL-37 has been observed to:

• Decrease keratinocyte apoptosis in certain skin models
• Increase interferon-alpha (IFN-α) production under specific stimulation conditions
• Influence chemotaxis of neutrophils and eosinophils
• Down-regulate toll-like receptor 4 (TLR4)–mediated signaling in selected systems
• Increase interleukin-18 (IL-18) production in some contexts
• Associate with reduced atherosclerotic plaque burden in certain experimental models

A notable feature is that LL-37 does not behave uniformly. For example, in T-cell research systems, LL-37 may enhance inflammatory actions when cells are not yet activated but may dampen inflammation once cells are already activated. This has led to the working hypothesis that LL-37 functions as a homeostatic modulator, helping fine-tune immune reactivity rather than driving a fixed pro- or anti-inflammatory outcome.

Antimicrobial Activity of LL-37
As part of the innate immune system, LL-37 is among the early-responding peptides during microbial challenge:

• Skin models: Baseline skin often shows low LL-37 levels, which can rise markedly upon exposure to microbial agents.
• Synergy with other peptides: LL-37 has been observed to act cooperatively with other endogenous peptides, such as human beta-defensin 2, in experimental infection models.
• LPS binding: LL-37 binds bacterial lipopolysaccharide (LPS), an essential component of gram-negative bacterial outer membranes, thereby disrupting microbial membrane integrity and contributing to direct antimicrobial effects.
• Gram-positive organisms: Despite its well-described interactions with LPS, LL-37 also demonstrates activity against gram-positive organisms and has been shown in vitro to enhance the effects of lysozyme against pathogens such as Staphylococcus aureus.

These properties make LL-37 a useful tool for studying multi-layered innate defense mechanisms in vitro and in vivo.

LL-37 and Lung Biology
In respiratory models, LL-37 has been studied in the context of airborne LPS exposure, toxic dust environments, and chronic airway disease:

• Epithelial response: LL-37 expression can increase in airway epithelial cells following exposure to irritants or microbial products.
• Wound closure and repair: Research indicates that LL-37 promotes airway epithelial cell migration and proliferation, supporting wound closure in in vitro and animal models.
• Angiogenesis and tissue homeostasis: LL-37 appears to contribute to coordinated repair responses by attracting structural cells and influencing local vasculature, underscoring its role as a potential homeostatic regulator in the airways.

These findings support the use of LL-37 as a model molecule for linking innate defense with epithelial repair in lung research.

LL-37 in Arthritis and Joint Inflammation
Elevated LL-37 levels have been reported in experimental models of joint inflammation, including those modeling rheumatoid arthritis:

• Presence in inflamed joints: LL-37 is detected in joint tissues and synovial fluid under inflammatory conditions, though current evidence does not support a direct pathogenic role.
• Protective hypotheses:
  • LL-37–derived peptides have been shown in animal models to protect against collagen damage and reduce disease severity scores in inflammatory arthritis research systems.
  • LL-37 has been associated with modulation of interleukin-32–driven inflammation, a cytokine linked to arthritis severity.
• Toll-like receptor pathways: LL-37 interacts with TLR pathways (e.g., TLR4), and ongoing work aims to clarify whether this interaction contributes to selective dampening of joint-destructive inflammatory responses.

Overall, LL-37 is being explored as a marker and potential modulator of inflammatory joint microenvironments rather than a primary cause of disease.

LL-37 and Intestinal Models
In gastrointestinal research, LL-37 has been evaluated for effects on epithelial barrier integrity, repair, and inflammation:

• Barrier maintenance: Cell culture studies show that LL-37 can enhance the migration of epithelial cells involved in maintaining the intestinal barrier.
• Apoptosis modulation: Under inflammatory conditions, LL-37 has been associated with reduced epithelial cell apoptosis, suggesting a possible protective effect on mucosal integrity.
• Combination with defensins: LL-37 appears to work alongside human beta-defensin 2 to promote wound closure and reduce TNF-related cell death in intestinal models.

These findings have led to interest in LL-37 as an experimental adjuvant in models of inflammatory bowel conditions, post-surgical healing, and antibiotic-associated gut injury—strictly at the research level.

LL-37, Cancer, and Blood Vessel Growth
The relationship between LL-37 and cancer is complex and context-dependent:

• Tumor microenvironment: In certain gastrointestinal and oral cancer models, LL-37 has been studied as part of vitamin D–responsive pathways in tumor-associated macrophages. These investigations look at how vitamin D–related signaling via LL-37 may influence local anti-tumor mechanisms.
• Angiogenesis: LL-37 can stimulate prostaglandin E2 (PGE2) production in endothelial cells, a mediator known to be involved in angiogenesis. This has implications for:
  • Modeling pro-angiogenic responses in wound healing and ischemic tissue
  • Exploring how altered angiogenesis may contribute to tumor growth or be targeted in cancer research

Through these lines of study, LL-37 is used as a tool to understand angiogenic control and the dual roles of inflammatory mediators in both repair and neoplastic processes.

Q1: What is LL-37 primarily used for in research?
A1: LL-37 is used to study innate immunity, antimicrobial defense, inflammatory signaling, tissue repair, and angiogenesis. It serves as a model peptide for understanding how one molecule can bridge host defense, immune modulation, and structural tissue responses.

Q2: Is LL-37 considered an antibiotic or a drug for treating infections?
A2: No. While LL-37 displays antimicrobial activity in experimental systems, LL-37 supplied for research is not approved or marketed as an antibiotic or therapeutic product. It is a research-only peptide used to explore host–pathogen interactions and innate immune mechanisms.

Q3: How does LL-37 affect inflammation in experimental models?
A3: LL-37 may either enhance or restrain inflammatory responses depending on cell type, activation state, and local cytokines. It has shown effects on cytokine production, cell recruitment, and pattern-recognition receptor signaling, making it a key peptide for investigating immune homeostasis rather than a simple pro- or anti-inflammatory factor.

Q4: Is LL-37 being investigated in connection with autoimmune or joint diseases?
A4: Yes. LL-37 has been detected in inflamed joints and has been studied in models of rheumatoid arthritis and other immune-mediated conditions. Current research focuses on its potential role as a modulator of inflammation and tissue damage, not as a confirmed therapeutic.

Q5: Can LL-37 be used for human therapy, cosmetic purposes, or self-administration?
A5: No. LL-37 distributed by research suppliers is intended strictly for laboratory use by qualified professionals. It is not approved for human or veterinary administration, cosmetic use, or any self-use application.